Cardiac injury, arrhythmia, and sudden death in a COVID-19 patient

Beri, Abhimanyu; Kotak, Kamal

doi:10.1016/j.hrcr.2020.05.001

Cited by 28 publications

(22 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 ). There were 24 case reports, 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 5 case series 29 , 30 , 31 , 32 , 33 and 2 cohort studies, 34 , 35 on a total of 51 cases of myocarditis and SARS-CoV-2 infection. The studies were of poor to fair quality due to the high risk of selection bias in case reports and small case series (Supplementary Table 1).…”

Section: Resultsmentioning

confidence: 99%

Coronavirus-induced myocarditis: A meta-summary of cases

et al. 2020

View full text Add to dashboard Cite

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

show abstract

Section: Resultsmentioning

confidence: 99%

Coronavirus-induced myocarditis: A meta-summary of cases

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Besides the typical clinical course of severe COVID-19, the sudden death due to cardiac arrhythmia and injury was also reported. 39 However, there is no obvious evidence for the increased risk of sudden cardiac death in cancer patients with COVID-19. Furthermore, increased risk of death in cancer patients administered CT within the last 30 days before COVID-19 diagnosis might be associated with the increased adverse events (AEs) rates of CT regardless of COVID-19.…”

Section: Discussionmentioning

confidence: 99%

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19

Yekedüz

Utkan

Ürün

2020

European Journal of Cancer

107

View full text Add to dashboard Cite

Background The COVID-19 pandemic hit all over the world and cancer patients are more vulnerable for COVID-19. Mortality rate may increase up to 25% in solid malignancies. In parallel to increased mortality rates among cancer patients, safety concerns regarding cancer treatment has increased over time. However, there were contradictory results for the cancer treatment during pandemic. In this study, we assessed the effect of cancer treatment on the severity of COVID-19. Methods The MEDLINE database was searched on September 01, 2020. Primary endpoints were severe disease and death in the cancer patients treated within the last 30 days before COVID-19 diagnosis. Quality of included studies were assessed by New Castle-Ottawa Scale. Generic inverse variance method was used to calculate odds ratios (ORs) for each outcome. Results Sixteen studies were included for this meta-analysis. Chemotherapy within the last thirty days before COVID-19 diagnosis increased the risk of death in cancer patients after adjusting for confounding variables (OR: 1.85; 95% CI:1.26-2.71). However, severe COVID-19 risk did not increase. Furthermore, targeted therapies, immunotherapy, surgery, and radiotherapy did not increase the severe disease and death risk in cancer patients with COVID-19. Conclusion Chemotherapy increased the risk of death from COVID-19 in cancer patients. However, there was no safety concern for immunotherapy, targeted therapies, surgery, and radiotherapy.

show abstract

“…Various forms of cardiac atrial and ventricular rhythm disorders have been reported in COVID-19 patients including atrial fibrillation, sinus tachycardia and bradycardia, complete conduction block and cardiac arrest [ 82 ]. Arrhythmia may associate with sudden cardiac death, which is a pathologic outcome also observed in COVID-19 patients [ [83] , [84] , [85] ]. Arrhythmia in COVID-19 patients is associated with myocardial injury and is thought to reflect the severity of illness [ 81 , 86 , 87 ].…”

Section: Sex Differences In Covid-19-related Cardiovascular Injurymentioning

confidence: 99%

Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19

Medzikovic¹,

Cunningham²,

Li³

et al. 2020

Journal of Molecular and Cellular Cardiology

View full text Add to dashboard Cite

The novel 2019 coronavirus disease (COVID-19), resulting from severe acute respiratory syndrome coronarvirus-2 (SARS-CoV-2) infection, typically leads to respiratory failure in severe cases; however, cardiovascular injury is reported to contribute to a substantial proportion of COVID-19 deaths. Preexisting cardiovascular disease (CVD) is among the most common risk factors for hospitalization and death in COVID-19 patients, and the pathogenic mechanisms of COVID-19 disease progression itself may promote the development of cardiovascular injury, increasing risk of in-hospital death. Sex differences in COVID-19 are becoming more apparent as mounting data indicate that males seem to be disproportionately at risk of severe COVID-19 outcome due to preexisting CVD and COVID-19-related cardiovascular injury. In this review, we will provide a basic science perspective on current clinical observations in this rapidly evolving field and discuss the interplay sex differences, preexisting CVD and COVID-19-related cardiac injury.

show abstract

Cardiac injury, arrhythmia, and sudden death in a COVID-19 patient

Cited by 28 publications

References 8 publications

Coronavirus-induced myocarditis: A meta-summary of cases

Coronavirus-induced myocarditis: A meta-summary of cases

A systematic review and meta-analysis: the effect of active cancer treatment on severity of COVID-19

Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19

Contact Info

Product

Resources

About